Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
2 Stocks Near 52-Week Highs That Could Climb Higher
05:33am, Monday, 28'th Nov 2022
This pair of stocks are bucking the trend and they could climb even higher.
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?
12:47pm, Thursday, 24'th Nov 2022
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
BIIB or RGEN: Which Is the Better Value Stock Right Now?
12:48pm, Wednesday, 23'rd Nov 2022
BIIB vs. RGEN: Which Stock Is the Better Value Option?
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned
Third FDA advisor resigns after Biogen's Alzheimer's drug approval
07:43am, Saturday, 19'th Nov 2022
A third FDA advisor has resigned following last week's controversial accelerated approval of Biogen's Alzheimer's drug.
This analyst breaks down the bull case for Biogen's Alzheimer's drug
04:37am, Saturday, 19'th Nov 2022
CNBC's Kelly Evans and Bertha Coombs discuss Biogen's new Alzheimer's drug and the battle for medicare coverage with Michael Yee of Jefferies.
Cramer: There will be push back on Biogen's Alzheimer's drug price
04:08am, Saturday, 19'th Nov 2022
The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living w
Biogen upgraded to 'overweight' at Piper Sandler
03:51am, Saturday, 19'th Nov 2022
CNBC's Morgan Brennan takes a look at the Nasdaq Biotech ETF and its best performer Biogen.
FDA approves Biogen Alzheimer's treatment
02:21am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports on FDA approval of Biogen's Alzheimer's treatment under an 'accelerated approval pathway.'
FDA's historic approval of Biogen's Alzheimer's drug
02:12am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell on the FDA approval of Biogen's new Alzheimer's drug. With CNBC's Brian Sullivan and the Fast Money traders, Guy Adami, Tim Seymour and Karen Mills
Is Biogen (BIIB) a Great Value Stock Right Now?
11:17am, Thursday, 17'th Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
3 Stocks to Avoid Right Now
09:23am, Thursday, 17'th Nov 2022
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
08:00am, Wednesday, 16'th Nov 2022
The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments
02:34pm, Monday, 14'th Nov 2022
Biogen's BIIB, +4.96% stock is rising again as investors double down on the company's promising yet still experimental treatment for Alzheimer's disease.
Biogen Stock Surges on Competitor's Downbeat Drug Data
10:57am, Monday, 14'th Nov 2022
While several sectors are taking a breather this morning, Biogen Inc (NASDAQ:BIIB) is climbing after major competitor Roche (ROG) said that its Alzheimer's drug candidate, gantenerumab, failed to meet
